I had a very good laugh a while back. A few actually. So many, they are worth sharing. 

T’was in May of this year when the storied New England Journal of Medicine published a study about a new and novel influenza vaccine, designed to conquer the seasonal flu. Lucky for us, this new bit of medical innovation was made from the same sort of whizbang mRNA technology that went into the Covid vaccines produced by Pfizer and Moderna. 

Yippee. Clearly this new jab is designed for those who didn’t get the joke last time when a big corporation came looking for us carrying a syringe full of what-the-heck-is-that?

But I digress. Even the premise of this vaccine study is like the setup to a stand-up routine, where you know that stuff is going to get weird fast. Soon you find some in the audience are busting a gut as others are looking befuddled and scratching their heads over which the joke flew. 

For starters, the biggest warning sign of any study is its size. A big study almost always means a small effect. Yup. In this case, to show some sort of effect they had to cadge together a group of over 40,000 people over 50, randomly injecting them with the trivalent mRNA-1010 or a “different licensed standard-dose flu shot” and following them for about 6 months. 

We’re all in the dark about what “mRNA 1010” is but rest assured that this “investigational messenger RNA (mRNA)-based vaccine encodes hemagglutinin glycoproteins from World Health Organization-recommended influenza strains.” That should make everyone start feeling all warm and fuzzy, thanking their lucky stars that the WHO........

© Eurasia Review